MYCN and neuroblastoma: In addition to neuroblastoma, increased MYCN activation, mainly through genomic amplification, is commonly observed in neuronal and neuroendocrine cancers [17,27], including medulloblastoma [28,29], Wilms tumor [30], retinoblastoma [31], neuroendocrine prostate cancer [32,33,34], glioblastoma [35,36], and small-cell lung cancer [37,38,39].